Protara Therapeutics develops transformative therapies for people with cancer and rare diseases with limited treatment options.
Protara Therapeutics develops transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy created for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.The Protara team prioritizes creativity, diverse perspectives, and tenacity to expedite their goal of bringing life-changing therapies to people with limited treatment options.